Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Published data pertaining to calcitonin gene-related peptide (CGRP) concentrations in human plasma are inconsistent. These inconsistencies may be due to the lack of a standardized, validated methodology to quantify this neuropeptide. Here, we describe a validated enzyme-linked immunosorbent assay (ELISA) protocol to purify and quantify CGRP in human plasma.
Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide that plays a putative role in the pathophysiology of migraine headaches and may be a candidate for biomarker status. CGRP is released from neuronal fibers upon activation and induces sterile neurogenic inflammation and arterial vasodilation in the vasculature that receives trigeminal efferent innervation. The presence of CGRP in the peripheral vasculature has spurred investigations to detect and quantify this neuropeptide in human plasma using proteomic assays, such as the enzyme-linked immunosorbent assay (ELISA). However, its half-life of 6.9 min and the variability in technical details of assay protocols, which are often not fully described, have yielded inconsistent CGRP ELISA data in the literature. Here, a modified ELISA protocol for the purification and quantification of CGRP in human plasma is presented. The procedural steps involve sample collection and preparation, extraction using a polar sorbent as a means of purification, additional steps to block non-specific binding, and quantification via ELISA. Further, the protocol has been validated with spike and recovery and linearity of dilution experiments. This validated protocol can theoretically be used to quantify CGRP concentrations in the plasma of individuals not only with migraine, but also with other diseases in which CGRP may play a role.
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that is present in neuronal fibers with perivascular localization as well as non-neuronal tissues. The two forms of CGRP, α- and β-CGRP, share more than 90% homology and share physiologic functions; however, αCGRP is found in the central and peripheral nervous system, while βCGRP is found in the enteric nervous system1,2. Upon nociceptor activation and calcium-dependent exocytosis, CGRP is released from neurons, inducing sterile neurogenic inflammation involving arterial vasodilatation and plasma protein extravasation
This protocol was developed using human plasma samples from consented individuals with approval from the Johns Hopkins Institutional Review Board (NA_00092491).
1. Sample collection and preparation
There are several key steps in the protocol that should be highlighted. Firstly, aprotinin, a serine protease inhibitor, must be added to whole blood samples immediately upon collection to prevent further enzymatic degradation of CGRP. Serine proteases have been shown to play a role in CGRP metabolism, and a previous study has also used aprotinin in quantifying CGRP in humans21,35. If protease inhibitors are not used, and sample preparation takes longer than 60 m.......
This article describes a validated protocol allowing for the detection and quantification of CGRP in human plasma. This protocol was synthesized after commercial CGRP ELISA kits were found to not accurately quantify this molecule. After establishing a sample preparation protocol and a valid standard curve, spike and recovery and linearity of dilution experiments showed that the percentage of recoveries were much lower than expected. Similar results were found using a different commercial CGRP ELISA kit (Table 4
The authors have no further disclosures to add.
We would like to thank Robert N. Cole, Lauren R. DeVine, and Marcos Iglesias for their helpful discussions regarding this protocol. This was supported in part by funding from the American Otological Society (Fellowship Grant, PSK), the American Hearing Research Foundation (90066548/90072266, JPC), and the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research (UL1 TR003098, NSF). The publication's contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH.
....Name | Company | Catalog Number | Comments |
1.7 mL Safeseal microcentrifuge tube | Sorenson Bioscience, Inc. | 11510 | |
99% methanol | ThermoFisher Scientific | L13255.0F | |
15 mL conical centrifuge tube | Falcon | 14-959-49B | |
2 mL round bottom sterile cryovials | CRYO.S | 122263 | |
4% acetic acid | ThermoFisher Scientific | 035572.K2 | |
6.0 mL Vacutainer EDTA collection tube | BD | 367863 | |
Allegra 64R benchtop centrifuge | Beckman Coulter, Inc. | 367586 | |
Aprotinin | VWR | 76344-814 | |
CGRP (human) ELISA kit | Bertin Bioreagent | A05481 | |
CGRP stock | Bertin Bioreagent | ||
EIA Buffer | Bertin Bioreagent | A07000 | |
Ellman's Reagent | Bertin Bioreagent | A09000_49+1 | |
Multichannel pipettes | ThermoFisher Scientific | 4661180N | |
Oasis HLB 3 cc Vac Cartridges | Waters | WAT094226 | |
Orbital Shaker | Bellco | 7744-01010 | |
Precision micropipettes | ThermoFisher Scientific | F144055MG | |
SpectraMax M Series Multi-Mode Microplate reader | Molecular Devices | Part Number M2 | |
TBS/Fish Gelatin | Bioworld, from Fischer Scientific | 50-199-167 | |
Ultrapure water ELISA Grade | Bertin Bioreagent | A07001 | |
Vacufuge plus - Centrifuge Concentrator | Eppendorf | 22820109 | |
Wash Buffer | Bertin Bioreagent | A17000 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone